Antimalarial Drug Resistance and Novel Targets for Antimalarial Drug Discovery

References

• Buffet PA, Safeukui I, Deplaine G, et al. The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood. 2011;117(2):381–392. doi:10.1182/blood-2010-04-20291120852127
   PubMed Web of Science ®Google Scholar
• Reyburn H. New WHO guidelines for the treatment of malaria. BMJ. 2010;340:c2637. doi:10.1136/bmj.c263720511305
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xie L, Xie L, Bourne P. The Plasmodium falciparum drugome and its polypharmacological implications. bioRxiv. 2016;042481.
   Google Scholar
• Cowman AF, Crabb BS. Invasion of red blood cells by malaria parasites. Cell. 2006;124(4):755–766. doi:10.1016/j.cell.2006.02.00616497586
   PubMed Web of Science ®Google Scholar
• Lee RS, Waters AP, Brewer JM. A cryptic cycle in haematopoietic niches promotes initiation of malaria transmission and evasion of chemotherapy. Nat Commun. 2018;9.
   Web of Science ®Google Scholar
• Woldearegai TG Characterization of Plasmodium falciparum mature gametocytes: lifespan, immunogenicity and susceptibility to novel compounds. 2018.
   Google Scholar
• Kondilis E, Giannakopoulos S, Gavana M, Ierodiakonou I, Waitzkin H, Benos A. Economic crisis, restrictive policies, and the population’s health and health care: the Greek case. Am J Public Health. 2013;103(6):973–979. doi:10.2105/AJPH.2012.30112623597358
   PubMed Web of Science ®Google Scholar
• Britton S, Cheng Q, McCarthy JS. Novel molecular diagnostic tools for malaria elimination: a review of options from the point of view of high-throughput and applicability in resource limited settings. Malar J. 2016;15(1):88. doi:10.1186/s12936-016-1158-026879936
   PubMed Web of Science ®Google Scholar
• Trampuz A, Jereb M, Muzlovic I, Prabhu RM. Clinical review: severe malaria. Crit Care. 2003;7(4):315. doi:10.1186/cc218312930555
   PubMed Web of Science ®Google Scholar
• O’Meara WP, Mangeni JN, Steketee R, Greenwood B. Changes in the burden of malaria in sub-Saharan Africa. Lancet Infect Dis. 2010;10(8):545–555. doi:10.1016/S1473-3099(10)70096-720637696
   PubMed Web of Science ®Google Scholar
• Sachs J, Malaney P. The economic and social burden of malaria. Nature. 2002;415(6872):680. doi:10.1038/415680a11832956
   PubMed Web of Science ®Google Scholar
• Organization WH. WHO malaria policy advisory committee meeting: meeting report, April 2018. World Health Organization;2018.
   Google Scholar
• Guerra CA, Snow RW, Hay SI. Mapping the global extent of malaria in 2005. Trends Parasitol. 2006;22(8):353–358. doi:10.1016/j.pt.2006.06.00616798089
   PubMed Web of Science ®Google Scholar
• Woldearegai TG, Kremsner PG, Kun JF, Mordmüller B. Plasmodium vivax malaria in Duffy-negative individuals from Ethiopia. Trans R Soc Trop Med Hyg. 2013;107(5):328–331. doi:10.1093/trstmh/trt01623584375
   PubMed Web of Science ®Google Scholar
• Deressa W, Olana D, Chibsa S. Magnitude of malaria admissions and deaths at hospitals and health centers in Oromia, Ethiopia. Ethiop Med J. 2004;42(4):237–246.16122115
   PubMedGoogle Scholar
• Ethiopia U. President’s malaria initiative Ethiopia-malaria operational plan FY 2017. 2017.
   Google Scholar
• Kumar S, Bhardwaj T, Prasad D, Singh RK. Drug targets for resistant malaria: historic to future perspectives. Biomed Pharmacother. 2018;104:8–27. doi:10.1016/j.biopha.2018.05.00929758416
   PubMed Web of Science ®Google Scholar
• Golenser J, Waknine JH, Krugliak M, Hunt NH, Grau GE. Current perspectives on the mechanism of action of artemisinins. Int J Parasitol. 2006;36(14):1427–1441. doi:10.1016/j.ijpara.2006.07.01117005183
   PubMed Web of Science ®Google Scholar
• Alam A, Goyal M, Iqbal MS, et al. Novel antimalarial drug targets: hope for new antimalarial drugs. Expert Rev Clin Pharmacol. 2009;2(5):469–489.22112223
   PubMedGoogle Scholar
• Plucinski MM, Talundzic E, Morton L, et al. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uíge provinces, Angola. Antimicrob Agents Chemother. 2015;59(1):437–443.25367912
   PubMed Web of Science ®Google Scholar
• Popovici J, Pierce-Friedrich L, Kim S, et al. Recrudescence, reinfection, or relapse? A more rigorous framework to assess chloroquine efficacy for Plasmodium vivax malaria. J Infect Dis. 2019;219(2):315–322.30102351
   PubMed Web of Science ®Google Scholar
• John GK, Douglas NM, Von Seidlein L, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J. 2012;11(1):280. doi:10.1186/1475-2875-11-28022900786
   PubMed Web of Science ®Google Scholar
• Fogh S, Jepsen S, Effersøe P. Chloroquine-resistant Plasmodium falciparum malaria in Kenya. Trans R Soc Trop Med Hyg. 1979;73(2):228–229. doi:10.1016/0035-9203(79)90220-7382468
   PubMed Web of Science ®Google Scholar
• Phillips EJ, Keystone JS, Kain KC. Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. Clin Infect Dis. 1996;23(5):1171–1173. doi:10.1093/clinids/23.5.11718922821
   PubMed Web of Science ®Google Scholar
• Rieckmann K, Davis D, Hutton D. Plasmodium vivax resistance to chloroquine? Lancet. 1989;334(8673):1183–1184. doi:10.1016/S0140-6736(89)91792-3
   Google Scholar
• Mohapatra M, Padhiary K, Mishra D, Sethy G. Atypical manifestations of Plasmodium vivax malaria. Indian J Malariol. 2002;39(1–2):18–25.14686106
   PubMedGoogle Scholar
• Rifakis PM, Hernandez O, Fernández CT, Rodriguez‐Morales AJ, Von A, Franco‐Paredes C. Atypical Plasmodium vivax malaria in a traveler: bilateral hydronephrosis, severe thrombocytopenia, and hypotension. J Travel Med. 2008;15(2):119–121. doi:10.1111/j.1708-8305.2007.00178.x18346245
   PubMed Web of Science ®Google Scholar
• Tan LK, Yacoub S, Scott S, Bhagani S, Jacobs M. Acute lung injury and other serious complications of Plasmodium vivax malaria. Lancet Infect Dis. 2008;8(7):449–454. doi:10.1016/S1473-3099(08)70153-118582837
   PubMed Web of Science ®Google Scholar
• Arnold J, Alving A, Hockwald E, et al. The antimalarial action of primaquine against the blood and tissue stages of falciparum malaria (Panama, PF-6 strain). J Lab Clin Med. 1955;46(3):391–397.13252317
   PubMed Web of Science ®Google Scholar
• Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009;42(3):267–278. doi:10.1016/j.bcmd.2008.12.00519233695
   PubMed Web of Science ®Google Scholar
• Tulu AN, Webber RH, Schellenberg JA, Bradley DJ. Failure of chloroquine treatment for malaria in the highlands of Ethiopia. Trans R Soc Trop Med Hyg. 1996;90(5):556–557. doi:10.1016/S0035-9203(96)90322-38944273
   PubMed Web of Science ®Google Scholar
• Sidhu ABS, Uhlemann A-C, Valderramos SG, Valderramos J-C, Krishna S, Fidock DA. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis. 2006;194(4):528–535. doi:10.1086/50711516845638
   PubMed Web of Science ®Google Scholar
• Paget-McNicol S, Saul A. Mutation rates in the dihydrofolate reductase gene of Plasmodium falciparum. Parasitology. 2001;122(5):497–505. doi:10.1017/S003118200100773911393822
   PubMed Web of Science ®Google Scholar
• Muller O. Challenges for control and elimination in the 21st century. Malaria Afri. 2011;60:193.
   Google Scholar
• Newton PN, Green MD, Mildenhall DC, et al. Poor quality vital anti-malarials in Africa-an urgent neglected public health priority. Malar J. 2011;10(1):352. doi:10.1186/1475-2875-10-35222152094
   PubMed Web of Science ®Google Scholar
• Hall KA, Newton PN, Green MD, et al. Characterization of counterfeit artesunate antimalarial tablets from southeast Asia. Am J Trop Med Hyg. 2006;75(5):804–811. doi:10.4269/ajtmh.2006.75.80417123969
   PubMed Web of Science ®Google Scholar
• Goldberg DE, Siliciano RF, Jacobs Jr WR. Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. Cell. 2012;148(6):1271–1283. doi:10.1016/j.cell.2012.02.02122424234
   PubMed Web of Science ®Google Scholar
• Bray P, Ward S, O’neill P. Quinolines and artemisinin: chemistry, biology and history In: Malaria: Drugs, Disease and Post-Genomic Biology. Springer-Verlag Berlin Heidelberg; 2005:3–38.
   Google Scholar
• White NJ. Counter perspective: artemisinin resistance: facts, fears, and fables. Am J Trop Med Hyg. 2012;87(5):785. doi:10.4269/ajtmh.2012.12-057323136172
   PubMed Web of Science ®Google Scholar
• Burrows JN, Duparc S, Gutteridge WE, et al. New developments in anti-malarial target candidate and product profiles. Malar J. 2017;16(1):26.28086874
   PubMed Web of Science ®Google Scholar
• Baker DA, Drought LG, Flueck C, et al. Cyclic nucleotide signalling in malaria parasites. Open Biol. 2017;7(12):170213. doi:10.1098/rsob.17021329263246
   PubMed Web of Science ®Google Scholar
• Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin C-S, Fleckenstein L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J. 2011;10(1):263. doi:10.1186/1475-2875-10-26321914160
   PubMed Web of Science ®Google Scholar
• Yeung S, Socheat D, Moorthy VS, Mills AJ. Artemisinin resistance on the Thai–Cambodian border. Lancet. 2009;374(9699):1418–1419. doi:10.1016/S0140-6736(09)61856-019854365
   PubMed Web of Science ®Google Scholar
• Lu F, Culleton R, Zhang M, et al. Emergence of indigenous artemisinin-resistant Plasmodium falciparum in Africa. N Engl J Med. 2017;376(10).
   Web of Science ®Google Scholar
• Baragaña B, Hallyburton I, Lee MC, et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature. 2015;522(7556):315. doi:10.1038/nature1445126085270
   PubMed Web of Science ®Google Scholar
• Yang Y-Z, Little B, Meshnick SR Alkylation of proteins by artemisinin: effects of heme, pH, and drug structure. 1994.
   Google Scholar
• Yang Y-Z, Asawamahasakda W, Meshnick SR Alkylation of human albumin by the antimalarial artemisinin. 1993.
   Google Scholar
• Eckstein-Ludwig U, Webb R, Van Goethem I, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature. 2003;424(6951):957. doi:10.1038/nature0181312931192
   PubMed Web of Science ®Google Scholar
• Hartwig CL, Rosenthal AS, D’angelo J, Griffin CE, Posner GH, Cooper RA. Accumulation of artemisinin trioxane derivatives within neutral lipids of Plasmodium falciparum malaria parasites is endoperoxide-dependent. Biochem Pharmacol. 2009;77(3):322–336. doi:10.1016/j.bcp.2008.10.01519022224
   PubMed Web of Science ®Google Scholar
• Inselburg J. Induction and isolation of artemisinine-resistant mutants of Plasmodium falciparum. Am J Trop Med Hyg. 1985;34(3):417–418. doi:10.4269/ajtmh.1985.34.4173890571
   PubMed Web of Science ®Google Scholar
• Chawira A, Warhurst D, Peters W. Qinghaosu resistance in rodent malaria. Trans R Soc Trop Med Hyg. 1986;80(3):477–480. doi:10.1016/0035-9203(86)90351-23541309
   PubMed Web of Science ®Google Scholar
• Gay F, Ciceron L, Litaudon M, et al. In-vitro resistance of Plasmodium falciparum to qinghaosu derivatives in West Africa. Lancet. 1994;343(8901):850–851. doi:10.1016/S0140-6736(94)92049-4
   Web of Science ®Google Scholar
• Haldar K, Bhattacharjee S, Safeukui I. Drug resistance in Plasmodium. Nat Rev Microbiol. 2018;16:156. doi:10.1038/nrmicro.2017.16129355852
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S, Stahelin RV, Haldar K. Host targeting of virulence determinants and phosphoinositides in blood stage malaria parasites. Trends Parasitol. 2012;28(12):555–562. doi:10.1016/j.pt.2012.09.00423084821
   PubMed Web of Science ®Google Scholar
• Carter TE, Boulter A, Existe A, et al. Artemisinin resistance-associated polymorphisms at the K13-propeller locus are absent in Plasmodium falciparum isolates from Haiti. Am J Trop Med Hyg. 2015;92(3):552–554. doi:10.4269/ajtmh.14-066425646258
   PubMed Web of Science ®Google Scholar
• Plowe CV, Roper C, Barnwell JW, et al. World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J. 2007;6(1):121. doi:10.1186/1475-2875-6-12117822535
   PubMed Web of Science ®Google Scholar
• Yayon A, Cabantchik Z, Ginsburg H. Identification of the acidic compartment of Plasmodium falciparum‐infected human erythrocytes as the target of the antimalarial drug chloroquine. EMBO J. 1984;3(11):2695–2700.6391917
   PubMed Web of Science ®Google Scholar
• Sanchez CP, Rohrbach P, McLean JE, Fidock DA, Stein WD, Lanzer M. Differences in trans‐stimulated chloroquine efflux kinetics are linked to PfCRT in Plasmodium falciparum. Mol Microbiol. 2007;64(2):407–420. doi:10.1111/j.1365-2958.2007.05664.x17493125
   PubMed Web of Science ®Google Scholar
• van Es HH, Renkema H, Aerts H, Schurr E. Enhanced lysosomal acidification leads to increased chloroquine accumulation in CHO cells expressing the pfmdr1 gene. Mol Biochem Parasitol. 1994;68(2):209–219. doi:10.1016/0166-6851(94)90166-X7739667
   PubMed Web of Science ®Google Scholar
• Sanchez CP, Rotmann A, Stein WD, Lanzer M. Polymorphisms within PfMDR1 alter the substrate specificity for anti‐malarial drugs in Plasmodium falciparum. Mol Microbiol. 2008;70(4):786–798.18713316
   PubMed Web of Science ®Google Scholar
• Raj DK, Mu J, Jiang H, et al. Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione. J Biol Chem. 2009;284(12):7687–7696. doi:10.1074/jbc.M80694420019117944
   PubMed Web of Science ®Google Scholar
• Kessl JJ, Lange BB, Merbitz-Zahradnik T, et al. Molecular basis for atovaquone binding to the cytochrome bc1 complex. J Biol Chem. 2003;278(33):31312–31318. doi:10.1074/jbc.M30404220012791689
   PubMed Web of Science ®Google Scholar
• Painter HJ, Morrisey JM, Mather MW, Vaidya AB. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. nature. 2007;446(7131):88. doi:10.1038/nature0557217330044
   PubMed Web of Science ®Google Scholar
• Lim MY-X, LaMonte G, Lee MC, et al. UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes. Nat Microbiol. 2016;1(12):16166. doi:10.1038/nmicrobiol.2016.16627642791
   PubMed Web of Science ®Google Scholar
• Chow ED, Lim L, Fidock DA, Diagana TT, Winzeler EA, Bifani P UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes. 2016.
   Google Scholar
• Kuhen KL, Chatterjee AK, Rottmann M, et al. KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. Antimicrob Agents Chemother. 2014;58(9):5060–5067. doi:10.1128/AAC.02727-1324913172
   PubMed Web of Science ®Google Scholar
• Jiang H, Patel JJ, Yi M, et al. Genome-wide compensatory changes accompany drug-selected mutations in the Plasmodium falciparum crt gene. PLoS One. 2008;3(6):e2484. doi:10.1371/journal.pone.000248418575593
   PubMed Web of Science ®Google Scholar
• Mwai L, Diriye A, Masseno V, et al. Genome wide adaptations of Plasmodium falciparum in response to lumefantrine selective drug pressure. PLoS One. 2012;7(2):e31623. doi:10.1371/journal.pone.003162322384044
   PubMed Web of Science ®Google Scholar
• Vestergaard LS, Ringwald P. Responding to the challenge of antimalarial drug resistance by routine monitoring to update national malaria treatment policies. Am J Trop Med Hyg. 2007;77(6_Suppl):153–159. doi:10.4269/ajtmh.2007.77.15318165488
   PubMed Web of Science ®Google Scholar
• Organization WH. Methods for surveillance of antimalarial drug efficacy. 2009.
   Google Scholar
• Oyelade J, Isewon I, Aromolaran O, et al. Computational identification of metabolic pathways of plasmodium falciparum using the-shortest path algorithm. Int J Genomics. 2019;2019.
   Web of Science ®Google Scholar
• Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov. 2004;3(6):509–520. doi:10.1038/nrd141615173840
   PubMed Web of Science ®Google Scholar
• Comer E, Beaudoin JA, Kato N, et al. Diversity-oriented synthesis-facilitated medicinal chemistry: toward the development of novel antimalarial agents. J Med Chem. 2014;57(20):8496–8502. doi:10.1021/jm500994n25211597
   PubMed Web of Science ®Google Scholar
• Mehta M, Sonawat HM, Sharma S. Glycolysis in Plasmodium falciparum results in modulation of host enzyme activities. J Vector Borne Dis. 2006;43(3):95.17024857
   PubMedGoogle Scholar
• Tilley L, Dixon MW, Kirk K. The Plasmodium falciparum-infected red blood cell. Int J Biochem Cell Biol. 2011;43(6):839–842. doi:10.1016/j.biocel.2011.03.01221458590
   PubMed Web of Science ®Google Scholar
• Dickerman BK, Elsworth B, Cobbold SA, et al. Identification of inhibitors that dually target the new permeability pathway and dihydroorotate dehydrogenase in the blood stage of Plasmodium falciparum. Sci Rep. 2016;6:37502. doi:10.1038/srep3750227874068
   PubMed Web of Science ®Google Scholar
• Kraft TE, Armstrong C, Heitmeier MR, Odom AR, Hruz PW. The glucose transporter PfHT is an antimalarial target of the HIV protease inhibitor lopinavir. Antimicrob Agents Chemother. 2015;AAC. 00899–00815.
   Web of Science ®Google Scholar
• Kirk K. Membrane transport in the malaria-infected erythrocyte. Physiol Rev. 2001;81(2):495–537. doi:10.1152/physrev.2001.81.2.49511274338
   PubMed Web of Science ®Google Scholar
• Heitmeier MR, Hresko RC, Edwards RL, et al. Identification of druggable small molecule antagonists of the Plasmodium falciparum hexose transporter PfHT and assessment of ligand access to the glucose permeation pathway via FLAG-mediated protein engineering. PLoS One. 2019;14(5):e0216457. doi:10.1371/journal.pone.021645731071153
   PubMed Web of Science ®Google Scholar
• Meireles P, Sales‐Dias J, Andrade CM, et al. GLUT1‐mediated glucose uptake plays a crucial role during Plasmodium hepatic infection. Cell Microbiol. 2017;19(2):e12646. doi:10.1111/cmi.12646
   Web of Science ®Google Scholar
• Jirage D, Keenan S,C, Waters N. Exploring novel targets for antimalarial drug discovery: plasmodial protein kinases. Infect Disorders Drug Targets. 2010;10(3):134–146.
   PubMedGoogle Scholar
• Lucet IS, Tobin A, Drewry D, Wilks AF, Doerig C. Plasmodium kinases as targets for new-generation antimalarials. Future Med Chem. 2012;4(18):2295–2310. doi:10.4155/fmc.12.18323234552
   PubMed Web of Science ®Google Scholar
• Derbyshire ER, Zuzarte‐Luís V, Magalhães AD, et al. Chemical interrogation of the malaria kinome. Chembiochem. 2014;15(13):1920–1930. doi:10.1002/cbic.20140002525111632
   PubMed Web of Science ®Google Scholar
• Ojo KK, Eastman RT, Vidadala R, et al. A specific inhibitor of Pf CDPK4 blocks malaria transmission: chemical-genetic validation. J Infect Dis. 2014;209(2):275–284. doi:10.1093/infdis/jit52224123773
   PubMed Web of Science ®Google Scholar
• Chapman TM, Osborne SA, Wallace C, et al. Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (Pf CDPK1). J Med Chem. 2014;57(8):3570–3587. doi:10.1021/jm500342d24689770
   PubMed Web of Science ®Google Scholar
• Banerjee R, Liu J, Beatty W, Pelosof L, Klemba M, Goldberg DE. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc Natl Acad Sci. 2002;99(2):990–995. doi:10.1073/pnas.02263009911782538
   PubMed Web of Science ®Google Scholar
• Shenai BR, Sijwali PS, Singh A, Rosenthal PJ. Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum. J Biol Chem. 2000;275(37):29000–29010. doi:10.1074/jbc.M00445920010887194
   PubMed Web of Science ®Google Scholar
• Eggleson KK, Duffin KL, Goldberg DE. Identification and characterization of falcilysin, a metallopeptidase involved in hemoglobin catabolism within the malaria parasite Plasmodium falciparum. J Biol Chem. 1999;274(45):32411–32417. doi:10.1074/jbc.274.45.3241110542284
   PubMed Web of Science ®Google Scholar
• Combrinck JM, Joanne E, Hearne GR, et al. Fate of haem iron in the malaria parasite Plasmodium falciparum. Biochem J. 2002;365(2):343–347. doi:10.1042/bj2002079312033986
   PubMed Web of Science ®Google Scholar
• Coronado LM, Nadovich CT, Spadafora C. Malarial hemozoin: from target to tool. Biochimica et Biophysica Acta. 2014;1840(6):2032–2041. doi:10.1016/j.bbagen.2014.02.00924556123
   PubMed Web of Science ®Google Scholar
• Vaidya AB, Mather MW. Mitochondrial evolution and functions in malaria parasites. Annu Rev Microbiol. 2009;63:249–267. doi:10.1146/annurev.micro.091208.07342419575561
   PubMed Web of Science ®Google Scholar
• Nixon GL, Pidathala C, Shone AE, et al. Targeting the mitochondrial electron transport chain of Plasmodium falciparum: new strategies towards the development of improved antimalarials for the elimination era. Future Med Chem. 2013;5(13):1573–1591. doi:10.4155/fmc.13.12124024949
   PubMed Web of Science ®Google Scholar
• Nina PB, Morrisey JM, Ganesan SM, et al. ATP Synthase Complex of Plasmodium falciparum dimeric assembly in mitochondrial membranes and resistance to genetic disruption. J Biol Chem. 2011;286(48):41312–41322. doi:10.1074/jbc.M111.29097321984828
   PubMed Web of Science ®Google Scholar
• Lunev S, Batista FA, Bosch SS, Wrenger C, Groves MR. Identification and validation of novel drug targets for the treatment of Plasmodium falciparum malaria: new insights. InTech. 2016.
   Google Scholar
• Sheridan CM, Garcia VE, Ahyong V, DeRisi JL. The Plasmodium falciparum cytoplasmic translation apparatus: a promising therapeutic target not yet exploited by clinically approved anti-malarials. Malar J. 2018;17(1):465. doi:10.1186/s12936-018-2616-730541569
   PubMed Web of Science ®Google Scholar
• Köhler S, Delwiche CF, Denny PW, et al. A plastid of probable green algal origin in Apicomplexan parasites. Science. 1997;275(5305):1485–1489. doi:10.1126/science.275.5305.14859045615
   PubMed Web of Science ®Google Scholar
• Wilson R. Parasite plastids: approaching the endgame. Biol Rev. 2005;80(1):129–153. doi:10.1017/S146479310400659115727041
   PubMed Web of Science ®Google Scholar
• Lim L, McFadden GI. The evolution, metabolism and functions of the apicoplast. Biol Sci. 2010;365(1541):749–763. doi:10.1098/rstb.2009.0273
   Web of Science ®Google Scholar
• Limenitakis J, Soldati-Favre D. Functional genetics in Apicomplexa: potentials and limits. FEBS Lett. 2011;585(11):1579–1588. doi:10.1016/j.febslet.2011.05.00221557944
   PubMed Web of Science ®Google Scholar
• Padmanaban G, Nagaraj VA, Rangarajan PN. Drugs and drug targets against malaria. Curr Sci. 2007;92(11).
   Web of Science ®Google Scholar
• McFadden GI, Roos DS. Apicomplexan plastids as drug targets. Trends Microbiol. 1999;7(8):328–333. doi:10.1016/S0966-842X(99)01547-410431206
   PubMed Web of Science ®Google Scholar
• Andersen S, Oloo A, Gordon D, et al. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in Western Ken. Clin Infect Dis. 1998;26(1):146–150. doi:10.1086/5162819455524
   PubMed Web of Science ®Google Scholar
• Taylor WR, Richie TL, Fryauff DJ, et al. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis. 1999;28(1):74–81. doi:10.1086/51507110028075
   PubMed Web of Science ®Google Scholar
• Gaynor BD, Amza A, Kadri B, et al. Impact of mass azithromycin distribution on malaria parasitemia during the low-transmission season in Niger: a cluster-randomized trial. Am J Trop Med Hyg. 2014;90(5):846–851. doi:10.4269/ajtmh.13-037924615132
   PubMed Web of Science ®Google Scholar
• Moore BR, Benjamin JM, Auyeung SO, et al. Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women. Br J Clin Pharmacol. 2016;82(1):199–212. doi:10.1111/bcp.1291026889763
   PubMed Web of Science ®Google Scholar
• Teixeira C, Gomes J, Gomes P. Falcipains, Plasmodium falciparum cysteine proteases as key drug targets against malaria. Curr Med Chem. 2011;18(10):1555–1572. doi:10.2174/09298671179532832821428877
   PubMed Web of Science ®Google Scholar
• Roy KK. Targeting the active sites of malarial proteases for antimalarial drug discovery: approaches, progress and challenges. Int J Antimicrob Agents. 2017;50(3):287–302. doi:10.1016/j.ijantimicag.2017.04.00628668681
   PubMed Web of Science ®Google Scholar
• Verma S, Dixit R, Pandey KC. Cysteine proteases: modes of activation and future prospects as pharmacological targets. Front Pharmacol. 2016;7:107. doi:10.3389/fphar.2016.0010727199750
   PubMed Web of Science ®Google Scholar
• Rosenthal PJ. Cysteine proteases of malaria parasites. Int J Parasitol. 2004;34(13–14):1489–1499.15582526
   PubMed Web of Science ®Google Scholar
• McKerrow JH, Sun E, Rosenthal PJ, Bouvier J. The proteases and pathogenicity of parasitic protozoa. Ann Rev Microbiol. 1993;47(1):821–853. doi:10.1146/annurev.mi.47.100193.0041338257117
   PubMed Web of Science ®Google Scholar
• Debrabant A, Delplace P. Leupeptin alters the proteolytic processing of P126, the major parasitophorous vacuole antigen of Plasmodium falciparum. Mol Biochem Parasitol. 1989;33(2):151–158. doi:10.1016/0166-6851(89)90029-72657420
   PubMed Web of Science ®Google Scholar
• Harris C, Hunte B, Krauss M, Taylor A, Epstein L. Induction of leucine aminopeptidase by interferon-gamma. Identification by protein microsequencing after purification by preparative two-dimensional gel electrophoresis. J Biol Chem. 1992;267(10):6865–6869.1551894
   PubMed Web of Science ®Google Scholar
• Grembecka J, Mucha A, Cierpicki T, Kafarski P. The most potent organophosphorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and activity. J Med Chem. 2003;46(13):2641–2655. doi:10.1021/jm030795v12801228
   PubMed Web of Science ®Google Scholar
• McGowan S, Porter CJ, Lowther J, et al. Structural basis for the inhibition of the essential Plasmodium falciparum M1 neutral aminopeptidase. Proc Natl Acad Sci. 2009;106(8):2537–2542. doi:10.1073/pnas.080739810619196988
   PubMed Web of Science ®Google Scholar
• Nankya-Kitaka M, Curley G, Gavigan C, Bell A, Dalton J. Plasmodium chabaudi chabaudi and P. falciparum: inhibition of aminopeptidase and parasite growth by bestatin and nitrobestatin. Parasitol Res. 1998;84(7):552–558. doi:10.1007/s0043600504479694371
   PubMed Web of Science ®Google Scholar
• Zhang R, Suwanarusk R, Malleret B, et al. A basis for rapid clearance of circulating ring-stage malaria parasites by the spiroindolone KAE609. J Infect Dis. 2016;213(1):100–104. doi:10.1093/infdis/jiv35826136472
   PubMed Web of Science ®Google Scholar
• Blascod DL, Wittyd MJ, Doninid C, et al.UCT943, a next generation Plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria 2. 2018.
   Google Scholar
• Schiafino-Ortega S, Baglioni E, Pérez-Moreno G, et al. 1, 2-Diphenoxiethane salts as potent antiplasmodial agents. Bioorg Med Chem Lett. 2018;28(14):2485–2489. doi:10.1016/j.bmcl.2018.05.06029880399
   PubMed Web of Science ®Google Scholar
• Belete TM. Novel targets to develop new antibacterial agents and novel alternatives to antibacterial agents. Human Microbio J. 2019;11:100052. doi:10.1016/j.humic.2019.01.001
   Google Scholar
• Almeida MR, Darin JD, Hernandes LC, Ramos M, Antunes LMG, Freitas O. Genotoxicity assessment of Copaiba oil and its fractions in Swiss mice. Genet Mol Biol. 2012;35(3):664–672. doi:10.1590/S1415-4757201200500005223055807
   PubMed Web of Science ®Google Scholar
• Batchvarova M, Shan S, Zennadi R, et al. Sevuparin Reduces Adhesion of Both Sickle Red Cells and Leukocytes to Endothelial Cells in vitro and Inhibits Vaso-Occlusion in Vivo. Washington, DC: American Society of Hematology; 2013.
   Google Scholar
• Mathews ES, John ARO. Tackling resistance: emerging antimalarials and new parasite targets in the era of elimination. F1000Research. 2018;7.
   Google Scholar
• Rosenthal PJ. Antimalarial drug discovery: old and new approaches. J Exp Biol. 2003;206(21):3735–3744. doi:10.1242/jeb.0058914506208
   PubMed Web of Science ®Google Scholar
• Ogeto T, Ndubi F, Murithi M, et al. Malaria vaccines targeting the pre-erythrocytic stage: a scoping review. F1000Research. 2020;9(680):680.
   Google Scholar
• Reis RA, Calil FA, Feliciano PR, Pinheiro MP, Nonato MC. The dihydroorotate dehydrogenases: past and present. Arch Biochem Biophys. 2017;632:175–191. doi:10.1016/j.abb.2017.06.01928666740
   PubMed Web of Science ®Google Scholar
• Rottmann M, Jonat B, Gumpp C, et al. Preclinical antimalarial combination study of M5717, a Plasmodium falciparum elongation factor 2 inhibitor, and pyronaridine, a hemozoin formation inhibitor. Antimicrob Agents Chemother. 2020;64(4).
   Web of Science ®Google Scholar
• Spillman NJ, Kirk K. The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs. Int J Parasitol Drugs Drug Resist. 2015;5(3):149–162.26401486
   PubMed Web of Science ®Google Scholar
• Phyo AP, Jittamala P, Nosten FH, et al. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label Phase 2 trial. Lancet Infect Dis. 2016;16(1):61–69. doi:10.1016/S1473-3099(15)00320-526448141
   PubMed Web of Science ®Google Scholar